CompanyGermanyUpdated Apr 30, 2026
FS Life Science Investment

FS Life Science Investment

FS Life Science Investment: Investor, Venture Capital • focus on Venture Capital, Impact • active in Germany, Europe • offices in Germany.

Never miss breaking news

Get instant notifications when new news matching "FS Life Science Investment" are published.

Company Profile

FS Life Science Investment is a German-based business angel firm dedicated to providing fair and sustainable funding to early-stage environmental and Life Science startups. The firm's core mission is to support companies that are actively working towards creating a positive impact on the planet, addressing critical global challenges such as climate change and the dramatic decline in biodiversity. They offer a combination of financial investment and hands-on mentorship to help entrepreneurs develop and scale their sustainable business ideas.

The firm was founded by Dr. Carmen Zirngibl and Dr. Frank Schäfer, who initiated their investment activities as business angels in 2012. Both founders bring a wealth of experience, with over 60 years of combined leadership in the Life Sciences sector. Dr. Zirngibl, who established DCZ Executive Search GmbH in 1997, joined FS Life Science Investment as a Managing Partner in 2012. Dr. Schäfer, a co-founder of BioEcho Life Sciences and Cube Biotech, has also been an active business angel since 2012. Their shared commitment to sustainability and a desire to empower the next generation of innovators underpin the firm's founding philosophy.

FS Life Science Investment's portfolio showcases its commitment to impactful ventures. Notable investments include BioEcho Life Sciences, a global biotech tools and genomic services company recognized for its pioneering efforts in integrating sustainability into molecular biology practices, which has successfully exited. Another key investment is Cube Biotech, a company providing essential biotech tools and services for protein research. More recently, the firm participated in the €4.1 million seed funding round for Primogene, a Leipzig-based biotech startup focused on the sustainable biomanufacturing of complex bioactive molecules. Additionally, WM Therapeutics (WMT AG), which is developing novel therapies for cancer and inflammation, is part of their investment portfolio.

The firm's strength lies in the extensive expertise of its founders. Dr. Carmen Zirngibl's background includes significant experience in executive search consultancy within the life sciences, healthcare, and technology sectors, complemented by a deep understanding of research and development. Dr. Frank Schäfer contributes broad experience in biotech, having held various R&D and General Management roles, co-founded multiple companies, and possessing profound knowledge in strategic development and fundraising. Together, they provide C-Suite mentoring, expert advice on recruiting, team building, and HR management, fostering a collaborative and supportive partnership with their portfolio companies, all driven by a strong passion for sustainability.

News & Signals (0)

No linked news activity found for this company.

Investor Listings

Similar Companies

Ranked by shared taxonomies: sector, subsector, geography, asset class and investor lists.

No similar companies found with overlapping taxonomy tags.